Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3)
Alain Amstutz,Frédérique Chammartin,Annette Audigé,Anna L Eichenberger,Dominique L Braun,Patrizia Amico,Marcel P Stoeckle,Barbara Hasse,Matthaios Papadimitriou-Olivgeris,Oriol Manuel,Cédric Bongard,Macé M Schuurmans,René Hage,Dominik Damm,Michael Tamm,Nicolas J Mueller,Andri Rauch,Huldrych F Günthard,Michael T Koller,Christof M Schönenberger,Alexandra Griessbach,Niklaus D Labhardt,Roger D Kouyos,Alexandra Trkola,Katharina Kusejko,Heiner C Bucher,Irene A Abela,Matthias Briel,Benjamin Speich,Abela I,Aebi-Popp K,Anagnostopoulos A,Battegay M,Bernasconi E,Braun D L,Bucher H C,Calmy A,Cavassini M,Ciuffi A,Dollenmaier G,Egger M,Elzi L,Fehr J,Fellay J,Furrer H,Fux C A,Günthard H F,Hachfeld A,Haerry D,Hasse B,Hirsch H H,Hoffmann M,Hösli I,Huber M,Jackson-Perry D,Kahlert C R,Kaiser L,Keiser O,Klimkait T,Kouyos R D,Kovari H,Kusejko K,Labhardt N,Leuzinger K,Martinez de Tejada B,Marzolini C,Metzner K J,Müller N,Nemeth J,Nicca D,Notter J,Paioni P,Pantaleo G,Perreau M,Rauch A,Salazar-Vizcaya L,Schmid P,Speck R,Stöckle M,Tarr P,Trkola A,Wandeler G,Weisser M,Yerly S,Patrizia Amico,John-David Aubert,Vanessa Banz,Sonja Beckmann,Guido Beldi,Christoph Berger,Ekaterine Berishvili,Annalisa Berzigotti,Isabelle Binet,Pierre-Yves Bochud,Sanda Branca,Heiner C Bucher,Emmanuelle Catana,Anne Cairoli,Yves Chalandon,Sabina De Geest,Olivier De Rougemont,Sophie De Seigneux,Michael Dickenmann,Joëlle Lynn Dreifuss,Michel Duchosal,Thomas Fehr,Sylvie Ferrari-Lacraz,Christian Garzoni,Déla Golshayan,Nicolas Goossens,Fadi Haidar,Jörg Halter,Dominik Heim,Christoph Hess,Sven Hillinger,Hans H Hirsch,Patricia Hirt,Linard Hoessly,Günther Hofbauer,Uyen Huynh-Do,Franz Immer,Michael Koller,Bettina Laesser,Frédéric Lamoth,Roger Lehmann,Alexander Leichtle,Oriol Manuel,Hans-Peter Marti,Michele Martinelli,Valérie McLin,Katell Mellac,Aurélia Merçay,Karin Mettler,Nicolas J Mueller,Ulrike Müller-Arndt,Beat Müllhaupt,Mirjam Nägeli,Graziano Oldani,Manuel Pascual,Jakob Passweg,Rosemarie Pazeller,Klara Posfay-Barbe,Juliane Rick,Anne Rosselet,Simona Rossi,Silvia Rothlin,Frank Ruschitzka,Thomas Schachtner,Stefan Schaub,Alexandra Scherrer,Aurelia Schnyder,Macé Schuurmans,Simon Schwab,Thierry Sengstag,Federico Simonetta,Susanne Stampf,Jürg Steiger,Guido Stirnimann,Ueli Stürzinger,Christian Van Delden,Jean-Pierre Venetz,Jean Villard,Julien Vionnet,Madeleine Wick,Markus Wilhelm,Patrick Yerly,the Swiss HIV Cohort Study,the Swiss Transplant Cohort Study
DOI: https://doi.org/10.1093/infdis/jiae291
2024-06-09
The Journal of Infectious Diseases
Abstract:Bivalent mRNA vaccines, designed to combat emerging SARS-CoV-2 variants, incorporate ancestral strains and a new variant. Our study assessed the immune response in previously vaccinated individuals of the Swiss HIV Cohort Study (SHCS) and the Swiss Transplant Cohort Study (STCS) following bivalent mRNA vaccination. Eligible SHCS and STCS participants received approved bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1–adapted BNT162b2) within clinical routine. Blood samples were collected at baseline, 4 weeks, 8 weeks, and 6 months post vaccination. We analyzed the proportion of participants with anti-spike protein antibody response ≥1642 units/ml (indicating protection against SARS-CoV-2 infection), and in a subsample T-cell response (including mean concentrations), stratifying results by cohorts and population characteristics. In SHCS participants, baseline anti-spike antibody concentrations ≥1642 were observed in 87% (96/112), reaching nearly 100% at follow-ups. Among STCS participants, 58% (35/60) had baseline antibodies ≥1642, increasing to 80% at 6 months. Except for lung transplant recipients, all participants showed a five-fold increase in geometric mean antibody concentrations at 4 weeks and a reduction by half at 6 months. At baseline, T-cell responses were positive in 96% (26/27) of SHCS participants and 36% (16/45) of STCS participants (moderate increase to 53% at 6 months). Few participants reported SARS-CoV-2 infections, side-effects, or serious adverse events. Bivalent mRNA vaccination elicited a robust humoral response in individuals with HIV or solid organ transplants, with delayed responses in lung transplant recipients. Despite a waning effect, antibody levels remained high at 6 months and adverse events were rare.
immunology,infectious diseases,microbiology